Novel substituted benzimidazole dosage forms and method of using same
AssigneeThe Curators of the University of Missouri
InventorJeffrey O. Phillips
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
Drawings
Claims150
A method of increasing absorption of a proton pump inhibiting agent into blood serum of a subject, comprising:
- providing a solid pharmaceutical composition for administration to the subject, the composition comprising the proton pump inhibiting agent and a buffering agent;
- and
- administering the pharmaceutical composition to the subject's stomach whereby the composition contacts gastric fluid of the stomach and increases the absorption of the proton pump inhibiting agent into the blood serum in an amount greater than the absorption of the proton pump inhibiting agent in the absence of the buffering agent;
- wherein the buffering agent is in an amount sufficient to increase gastric fluid pH of the stomach to a pH that inhibits acid degradation of the proton pump inhibiting agent in the gastric fluid so as to provide a measurable serum concentration upon pharmacokinetic testing.
19 The method of claim 1, wherein the amount of the buffering agent is at least 10 mEq.
A method of treating an acid related gastrointestinal disorder in a subject in need thereof, comprising:
- orally administering to the subject a solid pharmaceutical composition comprising a proton pump inhibiting agent and a buffering agent;
- wherein the buffering agent is in an amount sufficient to increase stomach content pH to a pH that inhibits acid degradation of the proton pump inhibiting agent in the stomach and to allow absorption of the proton pump inhibiting agent into blood serum of the subject in an amount greater than the absorption of the proton pump inhibiting agent in the absence of the buffering agent;
- and wherein the amount of proton pump inhibiting agent absorbed into the blood serum is therapeutically effective in treating the disorder.
55 The method of claim 37, wherein the amount of the buffering agent is at least 10 mEq.
A method of treating an acid related gastrointestinal disorder in a subject in need thereof, comprising:
- orally administering to the subject a pharmaceutical composition in an oral dosage form for immediate release into an absorption pool having a highly acidic pH, the composition comprising a proton pump inhibiting agent and a buffering agent;
- wherein the buffering agent is in an amount sufficient to increase the pH of the absorption pool of the subject to a pH that inhibits acid degradation of the proton pump inhibiting agent and to allow absorption of the proton pump inhibiting agent from the absorption pool into blood serum of the subject in an amount greater than the absorption of the proton pump inhibiting agent in the absence of the buffering agent;
- and
- wherein the proton pump inhibiting agent is in an amount sufficient to achieve a measurable serum concentration in the blood serum of the subject after oral administration to the subject.
93 The method of claim 75, wherein the amount of the buffering agent is at least 10 mEq.
A method of making a pharmaceutical composition for oral administration to a subject, providing immediate release of a proton pump inhibiting agent and a buffering agent into an absorption pool having a highly acidic pH, comprising:
- admixing the proton pump inhibiting agent and the buffering agent;
- wherein the buffering agent is in an amount sufficient to increase the pH of the absorption pool of the subject to a pH that inhibits acid degradation of the proton pump inhibiting agent and to allow absorption of the proton pump inhibiting agent from the absorption pool into blood serum of the subject in an amount greater than the absorption of the proton pump inhibiting agent in the absence of the buffering agent;
- and
- wherein the proton pump inhibiting agent is in an amount sufficient to achieve a measurable serum concentration in the blood serum of the subject after oral administration to the subject.
Dependencies are inferred from the claim text.